<DOC>
	<DOCNO>NCT01740089</DOCNO>
	<brief_summary>The purpose study demonstrate noninferiority Algeron 1.5 2.0 μg/kg/week combination ribavirin compare PegIntron combination ribavirin treatment chronic hepatitis C , determine therapeutic dose Algeron .</brief_summary>
	<brief_title>Algeron ( Cepeginterferon Alfa-2b ) Compared With PegIntron ( Peginterferon Alfa-2b ) Treatment Chronic Hepatitis C</brief_title>
	<detailed_description>After 12 week treatment , assessment treatment efficacy perform , i.e . rate rapid ( 4 week ) early ( 12 week ) virologic response accord serum HCV RNA level PCR data . In patient without virologic response 12 week , AVT discontinue , withdrawn study . Patients EVR enrol follow-up period . During follow-up period , patient first second group receive Algeron select therapeutic dose combination ribavirin , patient third group - PegIntron combination ribavirin 12 36 week ( depend genotype virus ) , afterwards follow without therapy 24 week .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>1 . Signed informed consent participate study . 2 . Hepatitis С virus infection ( genotypes 1а , 1b , 2 , 3 , 4 ) confirm positive quantitative PCR ( HCV RNA &gt; 50 IU/ml ) . 3 . Males female age 18 70 year inclusive . 4 . Body mass index 18 30 kg/m inclusive . 5 . Increased ALT level ( &gt; 40 , &lt; 400 IU/L ) , document least twice within last 6 month . 6 . Preserved protein synthetic liver function ( i.e . INR &lt; 1.7 , albumin &gt; 35 g/l ) . 7 . No sign hepatic encephalopathy abdominal fluid retention accord clinical ultrasound examination . 8 . Fertile patient partner agree use barrier contraception throughout study 7 month completion . 1 . Intolerance IFN alpha formulation , ribavirin component drug accord past medical history . 2 . Infection hepatitis B virus HIV . 3 . Past history HCV treatment IFN alfa pegylated IFN alfa formulation . 4 . Administration interferon and/or interferon inducing drug indication within 1 month prior enrollment study . 5 . Cholestatic hepatitis ( conjugated bilirubin , alkaline phosphatase , ALT level 5 ULN ) . 6 . Decompensated liver cirrhosis confirm laboratory finding ( ChildPugh class B , С ) ultrasound examination . 7 . Any documented autoimmune disease . 8 . Hematologic ( hemoglobin &lt; 130 g/L male &lt; 120 g/L female ; neutrophil &lt; 1.5 х109/L ; platelet &lt; 90 х109/L ) biochemical abnormality ( creatinine level 1.5 ULN , creatinine clearance le 50 mL/min ) . 9 . Documented diagnosis hemoglobinopathy ( e.g. , thalassemia major , sicklecell anemia ) . 10 . Heavy depression , mental disorder , Investigator 's opinion contraindication antiviral treatment . 11 . Epilepsy and/or functional disorder central nervous system . 12 . Abnormal thyroid function ( TTH level beyond normal value ) . 13 . Malignant neoplasm . 14 . Pregnancy , lactation period . 15 . Severe comorbidities ( example , severe hypertension , severe coronary heart disease , decompensated diabetes mellitus ) , Investigator 's opinion contraindication antiviral treatment . 16 . Documented rare hereditary disease , intolerance lactose , sucrose , fructose , lactase deficiency glucosegalactose malabsorption . 17 . Current alcohol drug abuse , Investigator 's opinion contraindication antiviral treatment restrict treatment compliance . 18 . Simultaneous participation clinical trial prior participation another clinical trial within less 30 day completion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Cepeginterferon alfa</keyword>
	<keyword>Peginterferon</keyword>
	<keyword>Treatment</keyword>
</DOC>